RECURRENT MULTIPLE MYELOMA
Clinical trials for RECURRENT MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited immune cells take on Hard-to-Treat myeloma in early trial
Disease control TerminatedThis early-phase trial tests a new treatment for multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in the lab using CRISPR gene editing to recognize and attack cancer cells. Abou…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail shows promise for Tough-to-Treat myeloma
Disease control OngoingThis early-stage trial tests a new drug (CB-839 HCl) combined with two standard treatments for multiple myeloma that has returned or is not responding. The main goal is to find the safest dose and see how well the combination works. About 36 adults with relapsed or refractory mul…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Multiple myeloma drug combo trial pulled before it even started
Disease control TerminatedThis early-stage trial aimed to test the safety and best dose of an experimental oral drug called selvigaltin when added to standard treatments for multiple myeloma that had come back or stopped responding. The study was withdrawn before enrolling any participants, so no results …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for Hard-to-Treat myeloma: drug combo targets resistant cancer
Disease control OngoingThis early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find the safest dose and see how well the body tolerates the r…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Abdullah Khan • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Four-Drug cocktail aims to tackle tough myeloma
Disease control OngoingThis phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for Hard-to-Treat myeloma: drug cocktail shows promise
Disease control OngoingThis study tests a combination of drugs (selinexor, pomalidomide, dexamethasone, and sometimes carfilzomib) in 39 adults with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combo controls the…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 03:00 UTC
-
Lab tests could pick the right drug for tough myeloma cases
Knowledge-focused OngoingThis study tests a new way to choose treatments for people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to standard therapy. Researchers use a lab test that checks many drugs at once, along with genetic information, to find which drug or d…
Matched conditions: RECURRENT MULTIPLE MYELOMA
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC